17 withdrawn. 17 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 17 | Withdrawn 17 |
| Phase 2 | 3 | Withdrawn 3 |
Follow Hydroxychloroquine: new trials by email Literature Review of Hydroxychloroquine trials Research Report on Hydroxychloroquine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| #StayHome: Early Hydroxychloroquine to Reduce Secondary Hospitalisation and Household Transmission in COVID-19 Hydroxychloroquine, Mannitol - COVID-19 | Phase 2 / Phase 3 | Withdrawn | Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland | 2022-01-01 | 2025-01-07 | |
| Azithromycin Plus Hydroxychloroquine for COVID-19 Infection Azithromycin plus hydroxychloroquine - Respiratory Tract Infection Viral | Phase 3 | Withdrawn | Iterum Therapeutics, International Limited | 2021-02-08 | 2021-10-28 | |
| The University of the Philippines Hydroxychloroquine PEP Against COVID-19 Trial Hydroxychloroquine plus standard preventive measures, Placebo plus standard preventive measures - COVID-19 | Phase 3 | Withdrawn | University of the Philippines | 2020-12-01 | 2020-11-06 | |
| PROphylaxis for paTiEnts at Risk of COVID-19 infecTion Hydroxychloroquine Sulfate 200 MG - COVID-19 | Phase 2 / Phase 3 | Withdrawn | Cambridge University Hospitals NHS Foundation Trust | 2020-09-01 | 2021-03-08 | |
| EVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRA Hydroxychloroquine and azithromycin treatment arm., Hydroxychloroquine, Control arm - Sars-CoV-2, Community-Acquired Pneumonia,COVID-19 | Phase 3 | Withdrawn | University Hospital, Strasbourg, France | 2020-06-02 | 2020-06-04 | |
| COVID-19 PEP- High-risk Individuals in Long-term and Specialized Care - Canada Hydroxychloroquine, Placebo - COVID-19 | Phase 3 | Withdrawn | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2020-05-30 | 2025-09-15 | |
| OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome Azithromycin, Hydroxychloroquine, Lopinavir 200Mg/Ritonavir 50Mg Tab - COVID | Phase 3 | Withdrawn | Fondation Hôpital Saint-Joseph | 2020-05-07 | 2021-04-27 | |
| Hydroxychloroquine or Diltiazem-Niclosamide for the Treatment of COVID-19 Standard of care (SOC), Hydroxychloroquine, Association of diltiazem and niclosamide - Sars-CoV2 | Phase 3 | Withdrawn | University Hospital, Lille | 2020-05-01 | 2021-03-11 | |
| Chloroquine Outpatient Treatment Evaluation for HIV-Covid-19 Chloroquine or hydroxychloroquine - Covid-19, HIV | Phase 3 | Withdrawn | University of Cape Town | 2020-05-01 | 2020-08-18 | |
| Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19) Hydroxychloroquine Sulfate, Hydroxychloroquine Sulfate + Azythromycin - Coronavirus Infections, SARS-CoV 2 | Phase 3 | Withdrawn | Apsen Farmaceutica S.A. | 2020-04-30 | 2026-09-08 | |
| Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health Professionals Hydroxychloroquine (HCQ), Placebo oral tablet - COVID19, Sars-CoV2 | Phase 3 | Withdrawn | Abderrahmane Mami Hospital | 2020-04-28 | 2020-08-28 | |
| Test and Treat COVID 65plus+ Hydroxychloroquine, Placebo - SARS-CoV 2, COVID-19 | Phase 2 / Phase 3 | Withdrawn | University Hospital Tuebingen | 2020-04-21 | 2021-01-15 | |
| HCQ for Primary Prophylaxis Against COVID19 in Health-care Workers Hydroxychloroquine, Placebo - Sars-CoV2, Infection Viral | Phase 3 | Withdrawn | Medical University of Vienna | 2020-04-01 | 2022-04-12 | |
| Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients Hydroxychloroquine and Azithromycin, Azinc - Covid-19 | Phase 3 | Withdrawn | Assistance Publique - Hôpitaux de Paris | 2020-04-01 | 2020-10-27 | |
| Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial) Hydroxychloroquine as post exposure prophylaxis, Others(No intervention) - Contact Person From COVID-19 Confirmed Patient | Phase 3 | Withdrawn | Gangnam Severance Hospital | 2020-04-01 | 2021-08-09 | |
| Hydroxychloroquine Azithromycin COVID-19 Pregnancy Trial Hydroxychloroquine and azithromycin treatment, conventional management of patients - COVID19 | Phase 3 | Withdrawn | Hospital St. Joseph, Marseille, France | 2020-04-01 | 2020-11-20 | |
| Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19 Hydroxychloroquine, Placebo oral tablet - COVID | Phase 3 | Withdrawn | Universidad Nacional de Colombia | 2020-03-30 | 2021-05-05 |
COVID-19 (12) · Coronavirus Infections (2) · Community-Acquired Pneumonia (1) · Dyspnea (1) · Lung Diseases (1) · Severe Acute Respiratory Syndrome (1) · Vasculitis (1) · Virus Diseases (1)
Abderrahmane Mami Hospital (1) · Apsen Farmaceutica S.A. (1) · Assistance Publique - Hôpitaux de Paris (1) · Cambridge University Hospitals NHS Foundation Trust (1) · Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland (1) · Fondation Hôpital Saint-Joseph (1) · Gangnam Severance Hospital (1) · Hospital St. Joseph, Marseille, France (1) · Iterum Therapeutics, International Limited (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · Medical University of Vienna (1) · Universidad Nacional de Colombia (1) · University Hospital Tuebingen (1) · University Hospital, Lille (1) · University Hospital, Strasbourg, France (1)
Brazil (1) · Colombia (1) · Germany (1) · Philippines (1) · South Africa (1) · South Korea (1) · Switzerland (1) · Tunisia (1) · United States (1)
Belen L Dofitas, MD (1) · Blaise Genton, MD-PhD (1) · Graeme Meintjes, PhD (1) · Jalila Ben Khelil, Pr (1) · Jean-Marc Naccache, MD (1) · Karine Faure, MD,PhD (1) · Mary-Anne Hartley, MD, PhD MPH (1) · Michael Dunne, MD (1) · Michael J Borrie, MB ChB (1) · Sean Wasserman, MBChB (1) · Thomas Hiemstra, PhD (1) · Yong Goo Song, Professor (1)